Chukwudi Udeogalanya is an associate in Weil’s Mergers & Acquisitions practice and is based in New York. Chukwudi participates in the representation of public and private companies in mergers, acquisitions and divestitures.
Chukwudi has been part of the teams advising:
- EO Charging in its proposed $675 million business combination with First Reserve Sustainable Growth Corp., a SPAC sponsored by First Reserve Corporation
- Hologic, Inc. in its $795 million acquisition of Mobidiag Oy
- Thea Pharma Inc. (a subsidiary of Laboratoires Théa SAS) in its acquisition of a portfolio of seven ophthalmic products from Akorn Pharmaceuticals
- Vonage Holdings Corp. in its pending $6.2 billion sale to Telefonaktiebolaget LM Ericsson
Prior to joining Weil, Chukwudi was an associate at another international law firm.
Chukwudi received his J.D. from Cornell Law School and his B.Sc. from SUNY Stony Brook.